相关实验视频

Updated: May 30, 2025

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Published on: May 12, 2023

发烧性中性质可以重新发明自己吗?

Aspasia Georgala¹, Jean Klastersky²

¹Département des Maladies Infectieuses, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet.

Current opinion in oncology

|January 27, 2025

概括

发烧性中性质不良症的治疗已经通过风险分层,生长因子和口服抗生素对特定患者进行了革命. 解决抗菌素耐药性对于有效的静脉注射治疗和持续的癌症治疗至关重要.

科学领域:

在瘤学瘤学.
血液学血液学血液学
传染性疾病传染性疾病

背景情况:

发烧性中性衰竭是细胞毒性化疗的重要并发症.
它影响了血液学和瘤学患者的治疗过程.
当前的管理策略正在随着新的治疗元素而发展.

研究的目的:

审查新元素和关键亮点,塑造当前发烧性中性质素质减退症的管理.
讨论热性中性衰竭治疗领域的进展.
为管理这种化疗并发症提供最新的视角.

主要方法:

审查当前的文献和临床实践.
对风险分层的近期进展进行分析.
对粒细胞殖民地刺激因子 (G-CSF) 和口服抗生素治疗的评估.

主要成果:

风险分层,G-CSF和口服抗生素已经改变了发烧性中性质不良症的治疗方法.
口服莫西弗洛克萨或阿莫西西林-克拉夫兰酸盐+西普罗夫洛克萨是选定的门诊患者的标准.
抗微生物药物耐药性对静脉注射发烧性中性质疏松症治疗构成重大挑战.

结论:

预防发烧性中性质和优化抗生素使用的策略是必不可少的.
严格的感染控制可以改善患者的治疗结果.
有效的管理允许不间断的抗瘤治疗.

更多相关视频

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...